Teva Pharmaceutical Industries Ltd. $TEVA Position Lifted by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. grew its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 360,316 shares of the company’s stock after acquiring an additional 18,093 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $6,039,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. New Age Alpha Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries during the first quarter worth about $43,000. Sound Income Strategies LLC raised its stake in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after buying an additional 2,824 shares in the last quarter. Banque Cantonale Vaudoise acquired a new stake in Teva Pharmaceutical Industries during the first quarter valued at approximately $74,000. CWM LLC lifted its holdings in Teva Pharmaceutical Industries by 18.1% during the 2nd quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after buying an additional 767 shares during the last quarter. Finally, Brooklyn Investment Group grew its position in shares of Teva Pharmaceutical Industries by 403.4% in the 1st quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after acquiring an additional 4,014 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 1.9%

Shares of NYSE:TEVA opened at $24.01 on Monday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The company’s 50-day moving average price is $19.74 and its 200 day moving average price is $17.89. The company has a market cap of $27.53 billion, a PE ratio of -150.03, a P/E/G ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $25.00.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, November 5th. The company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.68 by $0.10. The firm had revenue of $4.48 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. Teva Pharmaceutical Industries’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.69 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.86.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.